Pfeffer Cary's Form 4 filing
Jounce Therapeutics, Inc. (JNCE) · filed Nov 16, 2021
- Accession no.
- 0000899243-21-044914
- Filed
- Nov 16, 2021
- Trade date
- Nov 12, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Pfeffer CaryCIK 0001591092 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 12, 2021 | Common Stock | SSaleDisposed | 0 | $0.00F1 | $0 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On November 12, 2021, Third Rock Ventures III, L.P. ("TRV III") sold 1,900,000 shares of Common Stock of the Issuer at an average price per share of $8.38.
Referenced by the price of 1 transaction in Table I.